An interventional study of Bronchial artery embolization and Bronchial artery embolization combined with bronchoscopy in Bronchial Artery Embolization, Bronchoscopy and Hemoptysis, sponsored by Al-Azhar University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Al-Azhar University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aimed to evaluate the efficacy and safety of combining Bronchial artery embolization with bronchoscopy in the management of hemoptysis in patients with cavitary pulmonary tuberculosis.
The lungs have a dual arterial supply composed of the pulmonary and bronchial arterial systems. The pulmonary arteries account for 99% of the arterial supply and are responsible for gaseous exchange.
Combining bronchoscopy with Bronchial artery embolization may improve treatment outcomes and reduce recurrence rates. Despite the increasing use of Bronchial artery embolization, limited studies have evaluated the combined role of bronchoscopy and Bronchial artery embolization specifically in patients with cavitary pulmonary tuberculosis.
38 studies on the registry are indexed under Hemoptysis; 7 are open to participants now.
This study's planned enrollment of 30 is below the median of 72 across 21 interventional studies indexed under Hemoptysis.
Browse Hemoptysis studies →Al-Azhar University is the lead sponsor of 532 studies on the registry; 173 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will undergo bronchial artery embolization alone.
Procedure: Bronchial artery embolization
Patients will undergo bronchial artery embolization combined with bronchoscopy.
Procedure: Bronchial artery embolization combined with bronchoscopy
Patients will undergo bronchial artery embolization alone.
Patients will undergo bronchial artery embolization combined with bronchoscopy.
Proportion of Participants Achieving Successful Control of Hemoptysis
Percentage of participants achieving complete cessation of hemoptysis without requiring an additional intervention to control bleeding will be recorded.
Time frame: 24 hours after completion of the assigned intervention
Proportion of Participants With Recurrent Hemoptysis
Percentage of participants experiencing a new episode of hemoptysis after initial successful bleeding control will be recorded.
Time frame: 24 hours after completion of the assigned intervention
All-Cause Mortality
Percentage of participants who die from any cause during the specified follow-up period will be recorded.
Time frame: 24 hours after completion of the assigned intervention
Need for repeat embolization
Percentage of participants requiring an additional bronchial artery embolization procedure because of persistent or recurrent hemoptysis will be recorded.
Time frame: 24 hours after completion of the assigned intervention
Incidence of procedure-related complications
Incidence of procedure-related complications will be recorded.
Time frame: 24 hours after completion of the assigned intervention
Length of hospital stay
Length of hospital stay will be recorded from the admission till discharge from the hospital
Time frame: Till discharge from the hospital (Up to two weeks)
Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Supporting information: Study protocol
Time frame: After the end of study for one year.
Access criteria: The data will be available upon a reasonable request from the corresponding author.
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Sep 2028, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.